Given the early and ambiguous clinical data on A2-73, no big pharma is going to offer Anavex terms that would be acceptable to the board, to management or to stockholders. Anavex is not a secret to the players in AD and other CNS diseases. TGD had had a presence at virtually every conference of any significance for years. If there were real interest on acceptable terms, a collaboration would have happened by now. IMO, Anavex will have to continue without a partner unless and until there is a very compelling data set from larger, well designed, placebo-controlled P3 trials.